Streptozotocin (STZ) & High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

Creative Bioarray has extensive experience in researching nonalcoholic fatty liver disease (NAFLD) and provides clients worldwide with comprehensive preclinical services for NAFLD. Our team will work closely with you, assisting in the selection of appropriate models, designing study plans, and conducting final data analysis and reporting.

NAFLD is increasingly recognized as a significant liver manifestation of metabolic syndrome, which is closely linked to diabetes. Due to this strong association, there is widespread speculation that the connection between diabetes and hepatocellular carcinoma (HCC) may be intricately related to the progression of NAFLD. In order to delve deeper into this hypothesis and explore the potential role of nonalcoholic steatohepatitis (NASH) in the causal association between diabetes and HCC, we have meticulously established a NAFLD model induced by STZ in conjunction with a high-fat diet. This model allows us to simulate the metabolic disturbances observed in patients with diabetes and NAFLD, providing a robust platform for investigating the potential mechanisms underlying the progression from diabetes to HCC through the lens of NASH, as well as evaluating new therapies.

Our Streptozotocin (STZ) & High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

• Available Animal

Mouse

• Modeling Method

Neonatal C57BL/6 mice receive a single low-dose STZ injection two days after birth followed by administration of a high-fat diet after four weeks of age.

Fig. 1 Modeling method of streptozotocin (STZ) & high-fat diet -induced NAFLD model.

• Endpoints

• Body weight
• Liver weight
• Serum analysis: AST, ALT, TG, TC
• Histology analysis: H&E staining, Oil red O staining
• qPCR or Western blot
• Other customized endpoints

Example Data

Fig. 2 Omaveloxolone and analog TX63682 protect liver in the model of NASH. Representative photomicrographs are presented for histopathology (A), Oil Red O staining of fatty acids (C), and Sirius Red staining of collagen (E). NAFLD activity scores (B) and percent positive area for Oil Red O (D) and Sirius Red (F) are also presented. (Reisman et al. 2020)

Fig. 3 Effect of omaveloxolone and analog TX63682 on lipids. Serum total cholesterol (A), HDL cholesterol (B), LDL cholesterol (C), and triglycerides (D) were analyzed by HPLC. E, Liver triglycerides were quantified with the commercially available Triglyceride E‐test Kit. (Reisman et al. 2020)

Furthermore, we also provide other NAFLD models that maybe you are interested in:

• High-fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Methionine and Choline Deficient (MCD) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Gubra-Amylin NASH (GAN) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

Quotation and Ordering

Creative Bioarray has a group of seasoned experts who are not only specialized in establishing disease models but also experienced in data interpretation. With our rich experiences and cutting-edge techniques, we are confident to provide you with the first-class services to meet your exact research needs. If you are interested in our services, please feel free to contact us at any time or submit an inquiry to us directly.

Reference

1. Reisman, S.A., et al. Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis. Journal of Biochemical and Molecular Toxicology, 2020, 34(9): e22526.

Explore Other Options

• Alloxan-Induced Type 1 Diabetes Model
• Animal Model of Hyperuricemia
• High Fat Diet-Induced Obesity Model
• Nonalcoholic Fatty Liver Disease Model
• Type 1 Diabetes Mellitus Model

• Gubra-Amylin NASH (GAN) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Methionine and Choline Deficient (MCD) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

For research use only. Not for any other purpose.